Literature DB >> 22083990

Scutellarin attenuates human-neutrophil-elastase-induced mucus production by inhibiting the PKC-ERK signaling pathway in vitro and in vivo.

De-Peng Jiang1, Qi Li, Jie Yang, Juliy M Perelman, Victor P Kolosov, Xiang-Dong Zhou.   

Abstract

The aim of this study was to investigate the influence of scutellarin on mucus production induced by human neutrophil elastase (HNE) and the possible in vitro and in vivo mechanisms. To this purpose, cells were incubated with saline, scutellarin or gefitinib for 60 min and exposed to 0.1 μM HNE for 24 h. After being pretreated respectively with saline, scutellarin or gefitinib, rats were challenged intratracheally with HNE by means of nebulization for 30 days. The expression of mucin (MUC) 5AC, protein kinase C (PKC), and extracellular signal-regulated kinase 1/2 (ERK1/2) was assessed by ELISA, RT-PCR or Western blotting. The results showed that scutellarin inhibited MUC5AC mRNA and protein expressions induced by HNE in a concentration-dependent manner in vitro. In the in vivo model, scutellarin significantly attenuated MUC5AC mRNA expression and goblet cell hyperplasia in rats treated with HNE for 30 days, as well as decreased the phosporylation of PKC and ERK1/2 compared to the HNE control group. Therefore, our study showed that scutellarin could prevent mucus hypersecretion by inhibiting the PKC-ERK signaling pathway. Inhalation scutellarin may be valuable in the treatment of chronic inflammatory lung disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083990     DOI: 10.1142/S0192415X11009494

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  3 in total

Review 1.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

2.  Scutellarin Reduces Endothelium Dysfunction through the PKG-I Pathway.

Authors:  Xiaohua Du; Chen Chen; Min Zhang; Donghua Cai; Jiaqi Sun; Jian Yang; Na Hu; Congji Ma; Liyan Zhang; Jun Zhang; Weimin Yang
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-19       Impact factor: 2.629

3.  Scutellarin protects oxygen/glucose-deprived astrocytes and reduces focal cerebral ischemic injury.

Authors:  Jing-Bo Sun; Yan Li; Ye-Feng Cai; Yan Huang; Shu Liu; Patrick Kk Yeung; Min-Zhen Deng; Guang-Shun Sun; Prince Lm Zilundu; Qian-Sheng Hu; Rui-Xin An; Li-Hua Zhou; Li-Xin Wang; Xiao Cheng
Journal:  Neural Regen Res       Date:  2018-08       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.